التفاصيل البيبلوغرافية
| العنوان: |
Performance of Candidate Serum Biomarkers for Systemic Sclerosis–Associated Interstitial Lung Disease. |
| المؤلفون: |
Elhai, Muriel, Hoffmann‐Vold, Anna Maria, Avouac, Jérôme, Pezet, Sonia, Cauvet, Anne, Leblond, Agathe, Fretheim, Håvard, Garen, Torhild, Kuwana, Masataka, Molberg, Øyvind, Allanore, Yannick |
| المصدر: |
Arthritis & Rheumatology; Jun2019, Vol. 71 Issue 6, p972-982, 11p |
| مصطلحات موضوعية: |
BIOMARKERS, CARBON monoxide, CHEMOKINES, COMPUTED tomography, CONFIDENCE intervals, ENZYME-linked immunosorbent assay, GLYCOPROTEINS, INTERSTITIAL lung diseases, LONGITUDINAL method, MULTIVARIATE analysis, PULMONARY fibrosis, PULMONARY surfactant, RESPIRATORY measurements, PULMONARY function tests, RISK assessment, SURVIVAL, SYSTEMIC scleroderma, TUMOR necrosis factors, LOGISTIC regression analysis, SEVERITY of illness index, DISEASE progression, ODDS ratio, DISEASE complications, DISEASE risk factors |
| مستخلص: |
Objective: Interstitial lung disease (ILD) in systemic sclerosis (SSc) runs a highly variable course, and prediction tools are highly desired. The aim of this study was to assess the diagnostic and prognostic performance of 4 candidate serum biomarkers for SSc‐associated ILD. Methods: Serum samples from a combined cohort of SSc patients (from Paris, France and Oslo, Norway; n = 427) were analyzed by enzyme‐linked immunosorbent assay for concentrations of lung epithelial–derived surfactant protein D (SP‐D), Krebs von den Lungen 6 glycoprotein (KL‐6), CCL18, and OX40 ligand (OX40L). Lung fibrosis was measured by high‐resolution computed tomography and pulmonary function tests. Associations of these candidate biomarkers with baseline disease involvement and prediction of disease progression over time (mean ± SD follow‐up 3.2 ± 4.4 years) were investigated. Results: In SSc patients at baseline, serum levels of KL‐6 correlated with the forced vital capacity (FVC) (r = −0.317, P < 0.001), diffusing capacity for carbon monoxide (r = −0.335, P < 0.001), and extent of lung fibrosis (r = 0.551, P < 0.001). In multivariate analyses, serum levels of KL‐6 and SP‐D, but not CCL18 and OX40L, were associated with lung fibrosis (odds ratio [OR] 2.41, 95% confidence interval [95% CI] 1.43–4.07 [P = 0.001] and OR 3.15, 95% CI 1.81–5.48 [P < 0.001], respectively). In SSc patients with ILD at baseline, longitudinal, multivariate analyses showed that CCL18 serum levels were an independent predictor of a >10% decrease in the FVC (hazard ratio [HR] 2.90, 95% CI 1.25–6.73; P = 0.014) and de novo development of extensive disease (HR 3.71, 95% CI 1.02–13.52; P = 0.048). Matrix‐based logistic regression models for the diagnosis and prognosis of SSc‐associated ILD were constructed, and these models discriminated 3 groups of risk (mild, moderate, or high) for the diagnosis or worsening of lung fibrosis according to the serum levels of SP‐D (for diagnosis) and serum levels of CCL18 (for progression of disease). Conclusion: These results show that SP‐D is a relevant diagnostic biomarker for SSc‐associated ILD, whereas KL‐6 could be used to assess the severity of lung fibrosis. CCL18 appears to be a potential predictive marker for progression of ILD in SSc. [ABSTRACT FROM AUTHOR] |
|
Copyright of Arthritis & Rheumatology is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
Full Text Finder